CYNK-001 receives Fast Track designation from FDA for recurrent glioblastoma multiforme

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

CYNK-001, a natural killer cell therapy, has received Fast Track designation from FDA for the treatment of adults with recurrent glioblastoma multiforme.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
In This Issue

YOU MAY BE INTERESTED IN

Login